GCLM Cancer Research Results

GCLM, Glutamate-Cysteine Ligase Modifier Subunit: Click to Expand ⟱
Source:
Type:
The GCLM gene (Glutamate-Cysteine Ligase Modifier Subunit) is a key regulator of glutathione synthesis, which is essential for maintaining cellular redox balance and protecting against oxidative stress. The GCLM gene is overexpressed in various types of cancer.

GCLM gene is a key regulator of glutathione synthesis and is overexpressed in various types of cancer. Its expression is associated with poor prognosis and increased risk of metastasis and recurrence.
Scientific Papers found: Click to Expand⟱
1009- And,  5-FU,    Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer
- in-vivo, CRC, HCT116 - in-vitro, CRC, SW480
ChemoSen↑, Casp9↑, Ferroptosis↑, Wnt/(β-catenin)↓, FTL↑, TP53↑, ACSL5↑, GCLC↑, GCLM↑, SAT1↑, STEAP3↑, ACSL5↑,
3778- FA,    Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer’s Disease: A Narrative Review
- Review, AD, NA
*neuroP↑, *Aβ↓, *antiOx↑, *Inflam↓, *ROS↓, *NF-kB↓, *NLRP3↓, *iNOS↓, *COX2↓, *TNF-α↓, *IL1β↓, *VCAM-1↓, *ICAM-1↓, *p‑MAPK?, *hepatoP↑, *TLR4↓, *PPARγ↑, *NRF2↑, *Fenton↓, *IronCh↑, *MDA↓, *HO-1↑, *Bil↑, *GCLC↑, *GCLM↑, *NQO1↑, *GutMicro↑, *SOD↑, *Ca+2↓, *lipid-P↓, *PGE2↓,
3714- FA,    Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer's Disease: A Narrative Review
- Review, AD, NA
*antiOx↑, *Inflam↓, *neuroP↑, *NF-kB↓, *NLRP3↓, *iNOS↓, *COX2↓, *TNF-α↓, *IL1β↓, *VCAM-1↓, *ICAM-1↓, *p‑MAPK↓, *p38↓, *JNK↓, *IL6↓, *IL8↓, *hepatoP↑, *RenoP↑, *Catalase↑, *PPARγ↑, *ROS↓, *Fenton↓, *IronCh↑, *SOD↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *ARE↑, *Bil↑, *radioP↑, *GCLC↑, *GCLM↑, *NQO1↑, *Half-Life↝, *GutMicro↑, *Aβ↓, *BDNF↑, *Ca+2↓, *lipid-P↓, *PGE2↓, *cognitive↑, *ChAT↑, *memory↑, *Dose↝, *toxicity↓,
3311- SIL,    Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells
- in-vitro, Nor, PC12
*antiOx↑, *Inflam↓, AntiCan↑, *ROS↓, *MDA↓, *GSH↓, *NRF2↑, *GPx↑, *GCLC↑, *GCLM↑,
3399- TQ,    Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - NA, BC, MDA-MB-468
ROS↓, H2O2↓, Catalase↑, SOD↑, GSH↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, GSSG↑, GPx1⇅, GPx4↓,
4538- TQ,    Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD‐L1 in MDA‐MB‐231 Triple‐Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
antiOx↑, H2O2↓, Catalase↑, SOD↑, GSH↑, PRNP↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, chemoPv↑, ROS↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 2,   Ferroptosis↑, 1,   GCLC↑, 1,   GCLM↑, 3,   GPx1⇅, 1,   GPx4↓, 1,   GSH↑, 2,   GSSG↑, 1,   H2O2↓, 2,   NQO1↑, 2,   NRF2↑, 2,   ROS↓, 2,   SOD↑, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTL↑, 1,   STEAP3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL5↑, 2,   SAT1↑, 1,  

Cell Death(tgid=5) ⓘ

Casp9↑, 1,   Ferroptosis↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

TP53↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

PRNP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

PD-L1↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

PD-L1↓, 2,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoPv↑, 1,  
Total Targets: 29

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   ARE↑, 1,   Bil↑, 2,   Catalase↑, 1,   Fenton↓, 2,   GCLC↑, 3,   GCLM↑, 3,   GPx↑, 1,   GSH↓, 1,   HO-1↑, 2,   lipid-P↓, 3,   MDA↓, 3,   NQO1↑, 2,   NRF2↑, 3,   ROS↓, 3,   SOD↑, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PPARγ↑, 2,  

Cell Death(tgid=5) ⓘ

iNOS↓, 2,   JNK↓, 1,   p‑MAPK?, 1,   p‑MAPK↓, 1,   p38↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 2,   VCAM-1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   ICAM-1↓, 2,   IL1β↓, 2,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 3,   NF-kB↓, 2,   PGE2↓, 2,   TLR4↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 1,   ChAT↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,   NLRP3↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Bil↑, 2,   GutMicro↑, 2,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 1,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 2,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 1,  
Total Targets: 51

Scientific Paper Hit Count for: GCLM, Glutamate-Cysteine Ligase Modifier Subunit
2 Ferulic acid
2 Thymoquinone
1 Andrographis
1 5-fluorouracil
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:965  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page